Bausch + Lomb Corporation Common Shares (BLCO)
Stock · NYSE · Health Care
$16.48as of 10/16/2026
Price chart
BLCO Signal Track Record
How signals performed across all stocks →What BLCO's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 33 | +1.4% | 55% | August 27, 2026 |
| Bollinger Band Breakout | 19 | -2.0% | 37% | September 1, 2026 |
| 200-Day Moving Average TouchActive now | 17 | +2.7% | 65% | September 17, 2026 |
| Bollinger Band Breakdown | 16 | -0.1% | 50% | May 28, 2026 |
| Any 20-session window (baseline) | -0.1% | 49% |
Computed by MarketWall from daily closing prices since February 22, 2023. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About BLCO
Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequen…
- Sector
- Health Care
- Industry
- Ophthalmic Goods
- Employees
- 13,000
- Website
- ir.bausch.com/
Fundamentals
- 1-day range
- $16.25$16.81
- Market cap
- $5.84B
- P/E (trailing)
- —
- P/E (forward)
- 14.81
- EPS (trailing)
- $-0.48
- Dividend yield
- —
- Beta
- 0.55
- Avg. volume
- 449.3K
How Bausch + Lomb Corporation Common Shares Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 18, 2026 · via SEC EDGAR / Finnhub
Forecasts
14 analyst ratings
Bausch + Lomb Corporation Common Shares Competitors
Chosen by industry and closest market cap.
- BLCOBausch + Lomb Corporation Common Shares$16.49▼ 1.02%Market cap $5.84BP/E —$14.44$18.92
- WRBYWarby Parker Inc. Class A Common Stock$23.34▼ 5.08%Market cap $3.31BP/E 365.43$14.96$31
- EYENational Vision Holdings Inc. Common Stock$17.43▼ 1.30%Market cap $1.80BP/E 27.65$14.75$30.02
- STAASTAAR Surgical Company Common Stock$21.27▼ 4.45%Market cap $1.15BP/E 288.93$15.59$35.87
- RXSTRxSight Inc. Common Stock$4.51▼ 3.43%Market cap $251.69MP/E —$4.4$13.22
- LUCYInnovative Eyewear Inc. Common Stock$0.79▼ 6.29%Market cap $6.19MP/E —$0.65$2.05
- LUCYWInnovative Eyewear Inc. Series A Warrants 8/16/27$0.0251▼ 10.36%Market cap $556.8KP/E —$0.0251$0.152
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| BLCO Bausch + Lomb Corporation Common Shares | $5.84B | — | $16.49 | ▼ 1.02% | $14.44$18.92 |
| WRBY Warby Parker Inc. Class A Common Stock | $3.31B | 365.43 | $23.34 | ▼ 5.08% | $14.96$31 |
| EYE National Vision Holdings Inc. Common Stock | $1.80B | 27.65 | $17.43 | ▼ 1.30% | $14.75$30.02 |
| STAA STAAR Surgical Company Common Stock | $1.15B | 288.93 | $21.27 | ▼ 4.45% | $15.59$35.87 |
| RXST RxSight Inc. Common Stock | $251.69M | — | $4.51 | ▼ 3.43% | $4.4$13.22 |
| LUCY Innovative Eyewear Inc. Common Stock | $6.19M | — | $0.79 | ▼ 6.29% | $0.65$2.05 |
| LUCYW Innovative Eyewear Inc. Series A Warrants 8/16/27 | $556.8K | — | $0.0251 | ▼ 10.36% | $0.0251$0.152 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Why Is Bausch + Lomb Stock Falling Monday?benzinga · 10/12/2026
- SpyGlass Pharma Acquires Advanced Vision Science, Inc. (AVS), Securing Scalable Commercial IOL Supply and Accelerating Lens Portfolio Expansion CapabilityYahoo · 10/1/2026
- ‘Crisis of Its Own Creation’: Activist JANA Blasts Cooper, Demands CEO SearchBenzinga · 9/18/2026
- 3 Small-Cap Stocks That Concern UsYahoo · 9/17/2026
- Robinson Pharma, Inc. Receives "Above and Beyond" Supplier Award from Bausch + Lomb for September 2026Yahoo · 9/16/2026
- Bausch + Lomb Receives FDA Warning Letter Over Sterile Drug Manufacturing At Tampa Plant, Citing Inadequate Aseptic Controls And Persistent Microbial Contamination; Products Deemed AdulteratedBenzinga · 9/15/2026
- Needham Reiterates Hold on Bausch & Lombto HoldBenzinga · 9/15/2026
- Tracking Carl Icahn's 13F Report - Q2 2026 UpdateSeekingAlpha · 9/14/2026
- BLCO Gains European CE Mark for Next-Gen SeeLyra Femtosecond LaserYahoo · 9/14/2026
Insider Activity
Insider Actions →- Barbara Trebbi · August 12, 2026 · Grant11.8K
- Robert J. Chersi · August 12, 2026 · Grant11.8K
- Laurence E. Paul · August 12, 2026 · Grant11.8K
- Frederick Munsch · August 10, 2026 · Sale52.9K @ $16.78
- VON ESCHENBACH ANDREW C. · August 7, 2026 · Sale6.1K @ $16.58
- VON ESCHENBACH ANDREW C. · August 6, 2026 · Sale12.5K @ $16.5
- A. Robert D. Bailey · August 5, 2026 · Grant33.6K
- Sam Eldessouky · August 5, 2026 · Grant50.3K
- Andrew J. Stewart · August 5, 2026 · Grant16.8K
- Frederick Munsch · August 5, 2026 · Grant9.1K
- Yehia Hashad · August 5, 2026 · Grant21.0K
- Luc Bonnefoy · August 5, 2026 · Grant16.8K
- Brent L. Saunders · August 5, 2026 · Grant281.9K
- Brent L. Saunders · August 5, 2026 · Tax Withholding4.2K @ $16.76
- Luc Bonnefoy · June 12, 2026 · Tax Withholding1.0K @ $15.08
Institutional Ownership
March 31, 2026
- Total shares held
- 38.20M
- Total value held
- $583.82M
- Institutional holders
- 95
- Unknown3.53M
- Unknown3.50M
- Unknown3.38M
- Unknown3.15M
- Unknown2.66M
- Unknown2.25M
- Unknown2.20M
- Unknown2.00M
- Unknown1.91M
- Unknown1.26M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
BLCO Advances Oral Dry AMD Treatment After FDA Meeting
Bausch + Lomb reported progress on a new oral drug for dry age‑related macular degeneration after a constructive meeting with the FDA. The company said the discussion helped clarify the regulatory pathway and the drug’s development plan. It also announced that its third‑quarter 2026 earnings will be released on Oct. 28, giving investors a future update on performance.
BLCO Advances Oral Dry AMD Treatment After FDA Meeting. Bausch + Lomb reported progress on a new oral drug for dry age‑related macular degeneration after a constructive meeting with the FDA. The company said the discussion helped clarify the regulatory pathway and the drug’s development plan. It also announced that its third‑quarter 2026 earnings will be released on Oct. 28, giving investors a future update on performance.